Vanda Pharmaceuticals Inc.

Listed Company

VNDACIK 0001347178NasdaqAcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$216.10M

Net Income

$-220.47M

Total Assets

$488.95M

Equity

$327.19M

Shares Out

60.14M

Op. Cash Flow

$-109.44M

VNDA$5.44+11.60% · past yearDBEQ Basic

Daily closing prices

Business

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing innovative therapies for high unmet medical needs. The company's commercial portfolio includes four products: Fanapt® for schizophrenia and bipolar I disorder, HETLIOZ® for Non-24 and Smith-Magenis syndrome, PONVORY® for relapsing multiple sclerosis, and NEREUS™ for motion sickness prevention. The company operates in the U.S., Canada, Europe and Israel, distributing products through specialty pharmacies, specialty distributors and wholesalers.

Summary from 10-K filed 2026-02-12

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net product sales	216	199	193	254	269
Total revenues	216	199	193	254	269
Cost of goods sold excluding amortization	13	11	15	24	26
Research and development	109	74	77	86	75
Selling, general and administrative	238	146	113	136	124
Intangible asset amortization	7	7	2	2	1
Total operating expenses	367	239	207	248	227
Loss from operations	−151	−41	−14	6	42
Other income, net	13	18	20	5	199,000
Income (loss) before income taxes	−139	−23	6	11	42
Provision (benefit) for income taxes	82	−4	4	5	9
Net income (loss)	−220	−19	3	6	33
Basic (in dollars per share)	−3.74	−0.33	0.04	0.11	0.6
Diluted (in dollars per share)	−3.74	−0.33	0.04	0.11	0.58
Basic (in shares)	59	58	57	56	56
Diluted (in shares)	59	58	58	57	57

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	85	102	136	135	52
Marketable securities	179	272	252	332	381
Accounts receivable, net	55	47	34	34	32
Inventory	2	2	1	1	1
Prepaid expenses and other current assets	27	15	9	18	12
Total current assets	347	439	433	519	478
Property and equipment, net	2	2	2	3	3
Operating lease right-of-use assets	4	6	7	8	9
Finance lease right-of-use assets	7	5	0	—	—
Intangible assets, net	117	114	121	19	20
Deferred tax assets	0	81	75	74	75
Non-current inventory and other	11	9	10	11	8
Total assets	489	656	648	634	594
Accounts payable and accrued liabilities	68	39	38	46	34
Product revenue allowances	77	61	49	46	40
Total current liabilities	145	100	88	91	74
Operating lease non-current liabilities	3	5	7	9	10
Finance lease non-current liabilities	4	3	0	—	—
Other non-current liabilities	10	10	9	7	4
Total liabilities	162	118	104	107	89
Commitments and contingencies (Notes 11 and 18)	—	—	—	—	—
Preferred stock, $0.001 par value; 20,000,000 shares authorized, and no shares issued or outstanding at December 31, 2025 and 2024, respectively	0	0	0	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized; 59,101,630 and 58,310,644 shares issued and outstanding at December 31, 2025 and 2024, respectively	59,000	58,000	58,000	57,000	56,000
Additional paid-in capital	721	713	700	686	669
Accumulated other comprehensive income	629,000	74,000	−30,000	−1	−175,000
Accumulated deficit	−395	−174	−155	−158	−164
Total stockholders equity	327	539	545	527	505
Total liabilities and stockholders equity	489	656	648	634	594

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation of property and equipment	1	900,000	900,000	1	1
Stock-based compensation	9	12	14	16	15
Amortization of premiums and accretion of discounts on marketable securities	−2	−7	−9	−3	2
Loss on sales of marketable securities	0	0	655,000	0	−12,000
Right-of-use asset amortization	4	2	1	—	—
Deferred income taxes	81	−6	−1	1	7
Other non-cash adjustments, net	2	946,000	2	2	2
Accounts receivable	−7	−13	−707,000	−1	−2
Prepaid expenses and other assets	−12	−7	9	−6	−1
Inventory	−3	−29,000	−771,000	−4	−2
Accounts payable and other liabilities	16	2	−11	12	3
Product revenue allowances	15	12	3	6	6
Net cash provided by (used in) operating activities	−109	−16	13	32	64
Asset acquisition	0	−4	−101	0	0
Purchases of property and equipment	−998,000	−490,000	−383,000	−679,000	−552,000
Purchases of marketable securities	−112	−365	−513	−349	−420
Sales and maturities of marketable securities	208	352	602	400	344
Net cash provided by (used in) investing activities	95	−17	−12	50	−77
Principal payments on finance leases	−2	−155,000	0	0	—
Tax obligations paid in connection with settlement of restricted stock units	−915,000	0	0	—	—
Net cash provided by (used in) financing activities	−3	−155,000	0	734,000	4
Effect of exchange rate changes on cash, cash equivalents and restricted cash	23,000	−163,000	47,000	265,000	−91,000
Net change in cash, cash equivalents and restricted cash	−17	−34	792,000	83	−9

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Vanda Pharmaceuticals Inc.'s CIK number?

Vanda Pharmaceuticals Inc.'s SEC CIK number is 0001347178 (1347178). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Vanda Pharmaceuticals Inc.'s SEC filings?

All of Vanda Pharmaceuticals Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Vanda Pharmaceuticals Inc. last report earnings?

Vanda Pharmaceuticals Inc. (VNDA) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-031241). This is Vanda Pharmaceuticals Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Vanda Pharmaceuticals Inc.'s most recent earnings 8-K?

Vanda Pharmaceuticals Inc.'s latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001628280-26-031241. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Vanda Pharmaceuticals Inc.'s latest earnings 8-K →
Look up any company's CIK number →